Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma
复制标题
DOI：
10.1016/j.ijrobp.2015.04.005
复制
发表时间：
2015-08-01
影响因子：
7
通讯作者：
Robinson, Clifford G.
中科院分区：
文献类型：
--
作者：
Huang, Jiayi;DeWees, Todd A.;Robinson, Clifford G.
目的：急性重度淋巴细胞减少症(ASL)在放射治疗(RT)和替莫唑胺(TMZ)治疗高级别胶质瘤(HGG)过程中经常发生，并与生存率下降有关。方法与材料：自2007年1月至2012年12月，183例HGG患者接受RT+TMZ治疗，获得包括总淋巴细胞计数(TLC)和辐射剂量-体积直方图参数在内的有效数据。ASL定义为自RT开始后前3个月内的500只/亩L的TLC。结果：53例患者(29%)发生ASL。有ASL的患者总体生存率显著低于无ASL的患者(中位数分别为12.5个月和20.2个月，P
Purpose: Acute severe lymphopenia (ASL) frequently develops during radiation therapy (RT) and concurrent temozolomide (TMZ) for high-grade glioma (HGG) and is associated with decreased survival. The current study was designed to identify potential predictors of ASL, with a focus on actionable RT-specific dosimetric parameters.Methods and Materials: From January 2007 to December 2012, 183 patients with HGG were treated with RT+TMZ and had available data including total lymphocyte count (TLC) and radiation dose-volume histogram parameters. ASL was defined as TLC of < 500/mu L within the first 3 months from the start of RT. Stepwise logistic regression analysis was used to determine the most important predictors of ASL.Results: Fifty-three patients (29%) developed ASL. Patients with ASL had significantly worse overall survival than those without (median: 12.5 vs 20.2 months, respectively, P